Antibody-Drug Conjugate (ADC) – From Bioassay Development to Linker-Payload Constructs

WEBINAR

Antibody-drug conjugates (ADCs) represent a proven class of targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The development of robust bioassays for linker-payload constructs is crucial to ensure the efficacy and safety of ADCs. These bioassays enable the precise evaluation of linker stability, drug release, and the overall therapeutic activity of the conjugate. By optimizing these constructs, researchers can enhance the therapeutic window and minimize off-target effects, paving the way for more effective cancer treatments. Discovery biology and chemistry are challenged to meet the needs of the evolving space so as to advance early candidates efficiently and expand ADCs across non-oncolytic therapeutic areas.

In this webinar, we will discuss select examples of Curia’s experience in the ADC discovery space and how some of these challenges are overcome.

Key Learning Objectives: 

• Linker-Payload Design Elements: Gain insight into the different types of linkers and payloads used in antibody-drug conjugates, including mechanism of action and design considerations during linker-payload optimization.
• Conjugation and Characterization of ADCs: Understand stochastic bioconjugation and discovery scale ADC characterization.
• Explore the Different Bioassays Used to Screen ADCs: Learn the key principles and methodologies involved in developing robust bioassays for ADCs, focusing on assessing linker stability, internalization, drug release kinetics, and the therapeutic activity of the conjugates.